Original ArticleREMIFENTANIL (cas 132875-61-7) patient-controlled analgesia in labour: six-year audit of outcome data of the RemiPCA SAFE Network (2010–2015)
-
Add time:08/28/2019 Source:sciencedirect.com
BackgroundThe RemiPCA SAFE Network was established to set standards and monitor maternal and neonatal outcomes when using remifentanil for labour analgesia. The aim of this analysis was to describe the development of the network standard and to report maternal and neonatal outcome data, including severe adverse events.
We also recommend Trading Suppliers and Manufacturers of REMIFENTANIL (cas 132875-61-7). Pls Click Website Link as below: cas 132875-61-7 suppliers
Prev:Original ArticleSerious adverse events attributed to REMIFENTANIL (cas 132875-61-7) patient-controlled analgesia during labour in The Netherlands
Next:Original ArticleREMIFENTANIL (cas 132875-61-7) patient-controlled intravenous analgesia during labour: a retrospective observational study of 10 years’ experience) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Scientific ArticleREMIFENTANIL (cas 132875-61-7)–ketamine vs. propofol–ketamine for sedation in pediatric patients undergoing colonoscopy: A randomized clinical trialREMIFENTANIL (cas 132875-61-7)–cetamina vs. propofol–cetamina para sedação em pacientes pediátricos submetidos à colonoscopia: ensaio clínico randômico09/05/2019
- Clinical InformationSedation using dexmedetomidine and REMIFENTANIL (cas 132875-61-7) with local anesthesia for intraoperative speech monitoring: a case reportSedação com dexmedetomidina e REMIFENTANIL (cas 132875-61-7) em anestesia local para monitoração intraoperatória da fala: um relato de caso09/04/2019
- A physiologically-based model to predict individual pharmacokinetics and pharmacodynamics of REMIFENTANIL (cas 132875-61-7)09/03/2019
- REMIFENTANIL (cas 132875-61-7) attenuates lipopolysaccharide-induced oxidative injury by downregulating PKCβ2 activation and inhibiting autophagy in H9C2 cardiomyocytes09/02/2019
- Neuroscience and NeuroanaesthesiaREMIFENTANIL (cas 132875-61-7) as an adjunct to anaesthesia for electroconvulsive therapy fails to confer long-term benefits09/01/2019
- Annexin 1 inhibits REMIFENTANIL (cas 132875-61-7)-induced hyperalgesia and NMDA receptor phosphorylation via regulating spinal CXCL12/CXCR4 in rats08/31/2019
- Research paperOptimized PID control of propofol and REMIFENTANIL (cas 132875-61-7) coadministration for general anesthesia08/30/2019
- Original ArticleREMIFENTANIL (cas 132875-61-7) patient-controlled intravenous analgesia during labour: a retrospective observational study of 10 years’ experience08/29/2019
- Original ArticleSerious adverse events attributed to REMIFENTANIL (cas 132875-61-7) patient-controlled analgesia during labour in The Netherlands08/27/2019
